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Abstract
Background:  Proprotein convertase subtilisin/kexin type 9 (PCSK9) post-transcriptionally
degrades the low density lipoprotein receptors (LDLR). However, it is unknown whether PCSK9
acts directly on the LDLR or if PCSK9 activates another protein that in turn causes degradation of
the LDLR.
Results: We have transiently transfected HepG2 cells with wild-type and mutant D374Y-PCSK9
plasmids to study the effect of the conditioned medium on the LDLR of untransfected HepG2 cells.
The ability of the conditioned medium to reduce the internalization of LDL was abolished by
removal of recombinant PCSK9 from the conditioned medium by affinity chromatography. Thus,
PCSK9 is the only factor in the conditioned medium able to mediate degradation of the LDLR.
Moreover, fractionation of the conditioned medium by gel filtration showed that the ability of the
fractions to reduce the internalization of LDL, closely paralleled the amount of D374Y-PCSK9 in
the fractions. Incubation of a secreted, truncated LDLR without cytoplasmic and transmembrane
domains, as well as membrane fractions from HepG2 cells, with conditioned medium containing
PCSK9, did not reduce the amount of LDLR as determined by western blot analysis. Thus, the
LDLR is not degraded by PCSK9 on the cell surface. The LDLR of HepG2 cells incubated with
conditioned medium was protected from PCSK9-mediated degradation by the addition of
nocodazole or ammonium chloride, but was not protected when the conditioned medium was
made hypertonic. These findings indicate that the intracellular degradation of the LDLR involves
intracellular transport along microtubules, an acidic intracellular compartment and that it occurs
even when endocytosis through clathrin-coated pits has been blocked.
Conclusion: Degradation of the LDLR by PCSK9 is not mediated by a secreted protein acted
upon by PCSK9 extracellularly. Also the PCSK9-mediated degradation of the LDLR does not take
place on the cell surface. Rather, the PCSK9-mediated degradation of the LDLR appears to take
place intracellularly and occurs even when endocytosis through clathrin-coated pits is blocked by
hypertonic medium.
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Background
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a
proprotein convertase of the subtilase family [1,2]. It is
synthesized as a soluble zymogen which undergoes auto-
catalytic intramolecular cleavage in the endoplasmic retic-
ulum [1,2]. After cleavage, mature PCSK9 is efficiently
secreted as a complex with its prosegment and can be
found in the medium of cultured cells [1] and in human
plasma[3,4]. By the use of subcellular fractionation,
PCSK9 has been localized in endoplasmic reticulum and
the intermediate vesicular compartment, but not in Golgi
cisternae [5]. Even though the substrate for PCSK9 has not
been identified, PCSK9 has been shown to play a role in
cholesterol metabolism by regulating the number of cell
surface low density lipoprotein receptors (LDLR) [6-9].
Because PCSK9 reduces the number of LDLR without
reducing the amount of LDLR mRNA [6,7], degradation of
LDLR by PCSK9 is apparently a post-transcriptional event.
Both the LDLR and the PCSK9 genes are transcriptionally
regulated by sterol regulatory element-binding protein 2
[10,11]. Thus, both genes are upregulated when intracel-
lular levels of cholesterol are low. A role for PCSK9 in the
regulation of serum cholesterol levels in humans, is dem-
onstrated by the findings that mutations in the PCSK9
gene have been associated both with hypo- [12-14] and
hypercholesterolemia [15-20]. The mechanism by which
some mutations cause hypocholesterolemia, and others
cause hypercholesterolemia, is through reduced or
increased LDLR-degrading activity, respectively [21]. A
possible mechanism for the higher LDLR-degrading activ-
ity of the D374Y mutant PCSK9, is reduced inactivation
by the proprotein convertases furin and/or PC5/6A [4].
For the S127R mutant, increased secretion of apolipopro-
tein B-containing lipoproteins may contribute to the
hypercholesterolemia [22].
Degradation of the LDLR by PCSK9 is dependent on
maintained catalytic activity of PCSK9 [7,8] and appears
to take place in a post-Golgi compartment [7]. However,
the exact location for the degradation has not been iden-
tified. We have previously shown that conditioned
medium from HepG2 cells transiently transfected with a
PCSK9-containing plasmid, reduces the amount of cell
surface LDLR and internalization of LDL of untransfected
HepG2 cells [21]. Thus, PCSK9 or a factor acted upon by
PCSK9, is secreted from the transfected cells and degrades
the LDLR either directly or indirectly. Even though an
acidic compartment seems to be involved in degradation
of LDLR by PCSK9 [7,23], studies of ARH knock-out mice
suggest that internalization of LDLR is not required for the
LDLR to be degraded by PCSK9 [8]. Thus, degradation
may possibly take place on the cell membrane. However,
no degradation products of the LDLR has been identified
in culture medium of cells transfected with PCSK9 con-
structs. This indicates that PCSK9 may not simply cleave
the LDLR on the cell surface or that the cleaved LDLR is
rapidly degraded and has therefore escaped identification.
The ability of PCSK9 to degrade the LDLR is cell specific.
Overexpression of PCSK9 reduces the number of LDLR in
liver and kidney cells[8,23], but not in fibroblasts [8]. It is
therefore possible that PCSK9 may require another cell-
specific protein to exert its effect on the LDLR. Thus, the
exact mechanism by which PCSK9 degrades the LDLR
remains to be determined.
In this study we have examined the LDLR-degrading char-
acteristics of conditioned medium from HepG2 cells tran-
siently transfected with PCSK9-containing plasmids, to
provide information about the mechanism by which
PCSK9 degrades the LDLR. For these studies the PCSK9
cDNA construct containing mutation D374Y was prima-
rily used because of its higher LDLR-degrading activity
than the wild-type (WT) PCSK9 construct [4,21].
Results
Removal of PCSK9-His from conditioned medium restores 
internalization of LDL
PCSK9 could either degrade the LDLR by a direct interac-
tion, or PCSK9 could act on other proteins that in turn
cause degradation of the LDLR. Studies were therefore per-
formed to determine whether removal of PCSK9 from
conditioned medium affected the ability of conditioned
medum to reduce the internalization of LDL. For these
studies, conditioned media were prepared from HepG2
cells transiently transfected with WT-PCSK9-His plasmid,
D374Y-PCSK9-His plasmid or with empty plasmid. The
conditioned media were subjected to affinity chromatog-
raphy using columns containing a nickel-chelating resin
that binds His-tagged fusion proteins. Western blot anal-
ysis showed that all WT-PCSK9-His and D374Y-PCSK9-
His of the conditioned medium, had been removed from
the conditioned medium by the affinity chromatography
(Fig. 1). The slight upward shift of the band correspond-
ing to the mature PCSK9 in the medium, as compared to
the corresponding band in the lysate, is due to posttrans-
lational modification of secreted PCSK9 [1].
The effect of removing PCSK9-His from the conditioned
media on the internalization of LDL, was determined by
flow cytometry. Conditioned medium containing WT-
PCSK9-His or D374Y-PCSK9-His, reduced the internaliza-
tion of LDL by 38 (± 10)% (p < 0.01) and 73 (± 3)% (p <
0.0001), respectively, when compared to conditioned
medium obtained from HepG2 cells transfected with
empty plasmid (Fig. 2). After removal of WT-PCSK9-His
or D374Y-PCSK9-His from the conditioned medium by
affinity chromatography, the internalization of LDL was
significantly increased (p < 0.05 and p < 0.001, respec-BMC Cell Biology 2007, 8:9 http://www.biomedcentral.com/1471-2121/8/9
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tively). This post-affinity chromatographic increase in the
internalization of LDL was significantly greater (p <
0.005) than the post-affinity chromatographic increase in
the internalization of LDL caused by D374Y-PCSK9-FLAG
which does not bind specifically to the nickel-chelating
resin (Fig. 2). These findings indicate that PCSK9 is the
only protein in the conditioned medium that causes deg-
radation of the LDLR.
To further study whether the LDLR-degrading factor of the
conditioned medium was PCSK9 itself and not a second
protein acted upon by PCSK9, conditioned medium from
HepG2 cells transiently transfected with D374Y-PCSK9-
FLAG was fractionated by gel filtration on a Superdex 200
column. To determine the effect of the different fractions
on the internalization of LDL, HepG2 cells were incu-
bated with the individual fractions for 3 h at 37°C before
the amount of LDL internalized was determined by flow
cytometry. As can be seen from Fig. 3, cells incubated with
fraction 18 had the lowest amount of LDL internalized.
Slightly smaller reductions in the amount of LDL internal-
ized were observed with fractions 17 and 19. Proteins in
fraction 18 have a molecular hydrodynamic volume sim-
ilar to that of proteins with a molecular weight of approx-
imately 80 kDa. Western blot analysis of the fractions
using an anti-FLAG antibody, showed that D374Y-PCSK9-
FLAG were found in fractions 17–19 with the highest
amount in fraction 18 (Fig. 3). Thus, the ability of the frac-
tions to reduce the internalization of LDL, closely paral-
leled the amount of PCSK9 in the fraction. This finding
therefore supports the notion that degradation of the
LDLR by PCSK9, is caused by PCSK9 itself and not medi-
ated by a second extracellular protein acted upon by
PCSK9.
PCSK9 does not degrade a secreted truncated LDLR
To study whether WT-PCSK9 or D374Y-PCSK9 could
degrade the LDLR independent of any intracellular com-
partments, a truncated LDLR (EC-LDLR-His) lacking the
cytoplasmic and transmembrane domains of the LDLR
was used. Upon synthesis, this truncated LDLR is secreted
into the culture medium. Taking advantage of this, we
incubated medium containing EC-LDLR-His with condi-
tioned media containing either WT-PCSK9-His or D374Y-
PCSK9-His. Conditioned medium from HepG2 cells
transfected with empty-plasmid was used as a control.
After incubation, the amount of EC-LDLR-His was deter-
mined by western blot analysis using an anti-LDLR anti-
body. As can be seen from Figure 4A, no significant
difference in the amount of EC-LDLR-His was detected
after incubation with conditioned medium containing
WT-PCSK9-His or D374Y-PCSK9-His. This finding there-
fore suggests that PCSK9 does not degrade the LDLR by a
direct action on the extracellular part of the LDLR. How-
Affinity chromatography of PCSK9-His from conditioned medium Figure 1
Affinity chromatography of PCSK9-His from conditioned medium. Conditioned media from HepG2 cells transiently 
transfected with empty plasmid, wild-type (WT)-PCSK9-His plasmid or D374Y-PCSK9-His plasmid were loaded on affinity col-
umns containing a nickel-chelating resin. Conditioned medium before and after affinity chromatography was subjected to west-
ern blot analysis using an anti-PCSK9 antibody. Western blot analyses of cell lysates equivalent to 20 μg of protein per lane, 
were included to identify pro-PCSK9 and mature, cleaved PCSK9. Four independent experiments were performed from which 
one representative western blot is shown.
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ever, it is possible that degradation of the LDLR on the cell
surface by PCSK9 could require the presence of other cell
membrane proteins.
PCSK9 in conditioned medium does not degrade the LDLR 
of membrane fractions
In order to determine whether PCSK9 could degrade the
LDLR in the presence of other membrane proteins, mem-
brane fractions from HepG2 cell were prepared by ultra-
centrifugation. The membrane fractions were incubated
with conditioned medium from HepG2 cells transiently
transfected with empty plasmid, WT-PCSK9-His plasmid
or D374Y-PCSK9-His plasmid. Western blot analyses were
performed to determine the amount of LDLR in the mem-
brane fractions after incubation with the conditioned
media. As can be seen from Figure 4B, the presence of
PCSK9 in the conditioned media did not reduce the
amount of LDLR in the membrane fractions. This finding
indicates that even in the presence of other membrane
proteins, PCSK9 does not degrade the LDLR on the cell
surface. Thus, it seems that intact cells with intracellular
compartments are required for the PCSK9-mediated deg-
radation of the LDLR.
PCSK9-mediated degradation of LDLR occurs 
independently of clathrin-coated pits
To study whether endocytosis through clathrin-coated
pits is required for the PCSK9-mediated intracellular deg-
radation of the LDLR, conditioned medium was made
hypertonic by adding 150 mmol/l of NaCl in order to rap-
idly and reversibly block clathrin-coated pit formation
[24,25]. As a consequence of disruption of clathrin-coated
pits, the LDLR are distributed over the entire cell surface
[24]. In untransfected HepG2 cells incubated with hyper-
tonic, conditioned medium from HepG2 cells transiently
transfected with empty plasmid, the amount of LDL inter-
nalized was reduced to 12% (p < 0.01) as compared to
regular, isotonic conditioned medium (Fig. 5A). Similar
reduction in the internalization of LDL was also observed
with hypertonic, conditioned medium from HepG2 cells
transiently transfected with WT-PCSK9-FLAG or D374Y-
PCSK9-FLAG plasmids (Fig. 5A). Thus, when the condi-
Effect of conditioned medium depleted of PCSK9-His on the internalization of LDL Figure 2
Effect of conditioned medium depleted of PCSK9-His on the internalization of LDL. His-tagged PCSK9 was cleared 
from conditioned medium of HepG2 cells transiently transfected with empty plasmid, wild-type (WT)-PCSK9-His plasmid or 
D374Y-PCSK9-His plasmid, by affinity chromatography. Conditioned medium from HepG2 cells transfected with D374Y-
PCSK9-FLAG was also subjected to affinity chromatography as a control for a PCSK9 fusion protein which does not bind spe-
cifically to the nickel-chelating resin. The effect on internalization of LDL of the conditioned media before and after affinity 
chromatography, was studied by flow cytometry in untransfected HepG2 cells incubated with these media. Results represent 
mean (± SD) of four experiments. P-values are from comparisons between conditioned medium from transfections with empty 
plasmid on one hand and the PCSK9-containing media on the other hand (* p < 0.05, ** p < 0.01, *** p < 0.001).
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tioned medium was made hypertonic, the LDLR-medi-
ated uptake of LDL was severely reduced due to lack of
LDLR-mediated endocytosis of LDL through clathrin-
coated pits.
When the media were made hypertonic, the amount of
cell surface LDLR was reduced by 57% (p < 0.05) and 45%
(n.s.) in HepG2 cells incubated with conditioned
medium from HepG2 cells transfected with empty plas-
mid or the WT-PCSK9-His plasmid, respectively (Fig. 5B).
In HepG2 cells incubated with D374Y-PCSK9-His condi-
tioned medium, no significant change in the amount of
cell surface LDLR was observed in hypertonic medium.
Moreover, the amount of cell surface LDLR in hypertonic
D374Y-PCSK9-His medium remained significantly (p <
0.05) lower than the corresponding value obtained with
hypertonic, conditioned medium from HepG2 cells trans-
fected with empty plasmid (Fig. 5B). Thus, endocytosis
through clathrin-coated pits does not seem to be a prereq-
uisite for the intracellular degradation of the LDLR by
PCSK9.
To further study whether PCSK9 could enter HepG2 cells
independently of clathrin-coated pits, the uptake of a red-
tagged PCSK9 fusion protein (WT-PCSK9-Red) was stud-
ied by flow cytometry in HepG2 cells incubated with iso-
tonic or hypertonic medium. The amount of WT-PCSK9-
Red internalized is the difference between cell-associated
Gel filtration of conditioned medium from HepG2 cells transiently transfected with D374Y-PCSK9-FLAG plasmid Figure 3
Gel filtration of conditioned medium from HepG2 cells transiently transfected with D374Y-PCSK9-FLAG plas-
mid. Conditioned medium from HepG2 cells transiently transfected with D374Y-PCSK9-FLAG plasmid or with empty plasmid 
were concentrated approximately 10 times and 1 ml was loaded onto a Superdex 200 gel filtration column. Fractions of 2 ml 
were collected. HepG2 cells were incubated with the different fractions to determine the effect on internalization of LDL by 
flow cytometry. Fractions containing molecular weight standards are indicated on the x-axis. Aliquotes of fractions 15–21 were 
also subjected to precipitation of proteins by trichloroacetic acid. The amount of mature D374Y-PCSK9-FLAG in the fractions 
was determined by western blot analysis using an anti-FLAG antibody as shown in the insert.
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WT-PCSK9-Red at 37°C and at 4°C. As can be seen from
Fig. 6, HepG2 cells incubated with hypertonic medium
containing WT-PCSK9-Red, was able to take up WT-
PCSK9-Red although to a slightly lower extent (p < 0.05)
than cells incubated with isotonic medium. Thus, PCSK9
is able to enter HepG2 cells independently of clathrin-
coated pits.
Nocodazole or ammonium chloride inhibits degradation of 
the LDLR
Conditioned medium from HepG2 cells transiently trans-
fected with the D374Y-PCSK9-FLAG plasmid, reduced the
total amount of LDLR of untransfected HepG2 cells by
40% (p < 0.05) compared to conditioned medium from
cells transfected with empty plasmid (Fig. 7). In contrast,
conditioned medium from HepG2 cells transiently trans-
fected with the D374Y-PCSK9-FLAG plasmid did not
reduce the amount of cell membrane transferrin receptor
Efect of hypertonic, conditioned medium on internalization  of LDL and on the amount of cell surface LDLR Figure 5
Efect of hypertonic, conditioned medium on internal-
ization of LDL and on the amount of cell surface 
LDLR. HepG2 cells were transiently transfected with empty 
plasmid, WT-PCSK9-His plasmid or D374Y-PCSK9-His plas-
mid. Conditioned media from transfected cells were made 
hypertonic by addition of NaCl which increased the final con-
centration of NaCl by 150 mmol/l. The hypertonic medium 
was added to untransfected HepG2 cells for a 3 h incubation 
at 37°C. Isotonic, conditioned medium which had not been 
added NaCl was used as control. A) To measure internaliza-
tion of LDL the cells were added fluorescently labelled DiD-
LDL (10 μg/ml) and incubated for 2 h at 37°C. B) To meas-
ure the amounts of cell surface LDLR, the cells were labelled 
with anti-LDLR IgG-C7 antibody and counter-stained with 
Alexa Fluor® 488 goat anti-mouse IgG. Cell fluorescence was 
quantified by flow cytometry. Results represent mean (± SD) 
of three experiments (* p < 0.05, ** p < 0.01, *** p < 0.001).
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Effect of conditioned medium containing PCSK9 on a trun- cated LDLR (EC-LDLR-His) and on the LDLR in membrane  fractions Figure 4
Effect of conditioned medium containing PCSK9 on a 
truncated LDLR (EC-LDLR-His) and on the LDLR in 
membrane fractions. A) Medium containing a secreted, 
truncated LDLR (EC-LDLR-His) missing the cytosolic and 
transmembrane domains of the LDLR was concentrated and 
incubated for 3 h at 37°C with conditioned media from 
HepG2 cells transiently transfected with empty plasmid, WT-
PCSK9-His plasmid or the D374Y-PCSK9-His plasmid. B) 
HepG2 cell membrane fractions were isolated by ultracen-
trifugation and incubated for 3 h at 37°C with conditioned 
media from HepG2 cells transiently transfected with empty 
plasmid, WT-PCSK9-His plasmid or the D374Y-PCSK9-His 
plasmid. After incubations, both EC-LDLR-His and mem-
brane fractions (15 μg per lane) were subjected to western 
blotting in order to determine the amout of LDLR. For the 
membrane fractions, the amount of transferrin receptor 
(TFRC) was used as control. Three independent experiments 
were preformed from which one representative western 
blot is shown.
Membrane fraction
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(Fig. 7). Studies by others have suggested that degradation
of the LDLR by PCSK9 takes place in an acidic intracellular
compartment, possibly the lysosome [7,23]. Intracellular
transport of an LDLR-containing endosome to the lyso-
somes requires intact microtubules that are disrupted by
nocodazole [26]. To study whether nocodazole affected
the LDLR-degrading activity of the conditioned medium,
HepG2 cells were incubated for 3 h with conditioned
medium from HepG2 cells transiently transfected with
the D374Y-PCSK9-FLAG plasmid with or without addi-
tion of 20 μg/ml nocodazole. As can be seen in Fig. 7, noc-
odazole protected the LDLR from degradation by PCSK9.
Nocodazole seemed to increase the amount of LDLR in
cells incubated with conditioned medium from cells
transfected with empty plasmid. Addition of ammonium
chloride which increases the pH of acidic compartments
also protected the LDLR from degradation by the condi-
tioned medium (Fig. 7). The intracellular degradation of
the LDLR by PCSK9 therefore seems to require transport
along microtubules to an acidic compartment.
Discussion
In this report we have performed studies of the LDLR-
degrading activity of conditioned medium from HepG2
cells transiently transfected with PCSK9-containing plas-
mids. Such conditioned medium efficiently degrades the
LDLR of untransfected cells [21]. The PCSK9 plasmid con-
taining the mutation D374Y was primarily used as this
mutant has a higher LDLR-degrading activity than WT-
PCSK9 [4,21].
A key question regarding the mechanism by which PCSK9
degrades the LDLR, is whether PCSK9 acts directly upon
the LDLR or whether it activates another protein which in
turn causes degradation of the LDLR. To answer this ques-
tion, the effect of conditioned medium on the LDLR was
studied after D374Y-PCSK9-His had been removed by
affinity chromatography. The results clearly showed that
removal of WT-PCSK9-His or D374Y-PCSK9-His almost
completely abolished the ability of conditioned medium
to reduce the internalization of LDL. This indicates that
the LDLR-degrading activity of PCSK9 is not mediated by
another protein in the culture medium. The results of gel
filtration of conditioned medium from HepG2 cells tran-
siently transfected with D374Y-PCSK9-FLAG, showed that
the LDLR-degrading activity of the fractions closely paral-
Effect of nocodazole and ammonium chloride on PCSK9- mediated degradation of the LDLR Figure 7
Effect of nocodazole and ammonium chloride on 
PCSK9-mediated degradation of the LDLR. HepG2 
cells were cultured in media supplemented with nocodazole 
(20 μg/ml) or ammonium chloride (NH4Cl, 10 mM) for 30 
min. The media were then replaced with conditioned media 
from HepG2 cells transiently transfected with D374Y-PCSK9-
FLAG plasmid or with empty plasmid, already containing 
ammonium chloride or nocodazole, and the incubation was 
continued for 3 h. The conditioned media had also been 
added ammonium chloride or nocodazole. Cell membranes 
were isolated and membrane proteins equivalent to 10 μg 
were subjected to western blot analysis to determine the 
amount of LDLR. The amount of transferrin receptor 
(TFRC) was used as a control. Band intensities were quanti-
fied using a ChemiDoc XRS and Quantity One version 4.4.0 
software. Results represent the mean (± SD) of four experi-
ments, from which one representative western blot is 
shown.
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Effect of hypertonic medium on internalization of WT- PCSK9-Red Figure 6
Effect of hypertonic medium on internalization of 
WT-PCSK9-Red. Conditioned medium from HepG2 cells 
transiently transfected with WT-PCSK9-Red plasmid was 
made hypertonic by addition of NaCl which increased the 
final concentration of NaCl by 150 mmol/l. The hypertonic, 
conditioned medium was added to untransfected HepG2 
cells for 3 h incubations at 37°C or at 4°C. Isotonic, condi-
tioned medium is conditioned medium without addition of 
NaCl. Amounts of cell-associated WT-PCSK9-Red were 
determined by flow cytometry. Control is medium without 
WT-PCSK9-Red. Results represent mean (± SD) of three 
experiments (** p < 0.01, *** p < 0.001).
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leled the amount of D374Y-PCSK9-FLAG in the fractions.
This finding shows that PCSK9 purified by gel filtration
degrades the LDLR when added back to cultured cells.
Moreover, it suggests that PCSK9 degrades the LDLR in a
dose-dependent manner. This finding also supports the
notion that PCSK9 is the only extracellular protein
involved in the degradation of LDLR. The possibility that
the active form of PCSK9 was PCSK9 complexed with
another soluble protein is unlikely as the proteins of the
fraction obtained by gel filtration which had the highest
LDLR-degrading activity, had a molecular hydrodynamic
volume similar to that of proteins with a molecular weight
of approximately 80 kDa. This is close to the molecular
weight of approximately 75 kDa of mature PCSK9 com-
plexed to its prosegment [1]. Together, these data indicate
that PCSK9 is the only extracellular protein which causes
degradation of the LDLR. These data also indicate that
PCSK9 appears extracellularly as a monomer, and is not
complexed to another protein. Consequently, the expla-
nation for the cell-specific effect of PCSK9 on degradation
of the LDLR, does not appear to be that PCSK9 requires a
secreted cell-specific protein to degrade the LDLR. How-
ever, it is possible that PCSK9 may require the presence of
cell-specific membrane-bound or cytosolic proteins to
degrade the LDLR.
The failure of the secreted, truncated LDLR (EC-LDLR-
His), which lacks the cytoplasmic and membrane-span-
ning domains, to be degraded when incubated with con-
ditioned medium, indicates that PCSK9 does not degrade
the LDLR directly by acting on the extracellular part of the
LDLR. It is possible that degradation of the LDLR on the
cell surface, could require a cell membrane protein not
present in the pure preparation of the truncated EC-LDLR-
His. However, incubation of membrane fractions with
conditioned media did not lead to degradation of the
LDLR of the membrane fractions. Thus, even in the pres-
ence of other membrane proteins, PCSK9 does not
degrade the cell surface LDLR. It therefore seems that
PCSK9 and/or the LDLR need to be internalized in order
for PCSK9 to degrade the LDLR.
Our finding that D374Y-PCSK9-His was able to reduce
the number of cell surface LDLR even when clathrin-
coated pits were blocked by hypertonic medium, suggests
that the intracellular degradation of the LDLR by PCSK9
does not involve endocytosis through clathrin-coated pits.
This finding is therefore in agreement with the finding
that functional ARH is not required for PCSK9 to degrade
the LDLR in mice overexpressing PCSK9 [8]. However,
these findings are at variance with the finding of Lagace et
al. [27], which was published during review of our paper,
who found that functional ARH is required for PCSK9 to
degrade the LDLR when added exogenously to primary
hepatocytes. The explanation for these conflicting data
could be that compensatory clathrin-independent endo-
cytotic pathways may become activated when the clathrin-
coated pits are artificially blocked or when PCSK9 is over-
expressed. The notion that the intracellular degradation of
the LDLR may be independent of how the LDLR and
PCSK9 enter the cells, is supported by the findings in HEp-
2 cells where molecules endocytosed through clathrin-
independent mechanisms were delivered to endosomes
containing cargo which had been endocytosed through
clathrin-coated pits [28]. Even though our studies show
that clathrin-independent endocytosis is able to mediate
the degradation of the LDLR by PCSK9, it is still possible
that clathrin-dependent endocytosis may be the predom-
inant pathway by which LDLR and PCSK9 enter the cells
in vivo.
Both we, in this study, and others [7,23] have found that
addition of ammonium chloride protects the LDLR from
PCSK9-mediated degradation. This suggests that an acidic
compartment is involved in the degradation of the LDLR.
Together with our finding that nocodazole also protects
the LDLR from degradation, transport of endosomes con-
taining LDLR along microtubules to an acidic compart-
ment seems to be involved in the degradation of LDLR by
PCSK9. This notion is supported by the findings of Ben-
jannet et al. [4] who have found present PCSK9 in both
early and late endosomes. It is also supported by the
recent data of Lagace et al. [27] who found that PCSK9
and LDLR associate and can be found in late endocytic
compartments. They also found that administration of
purified PCSK9 to the medium of HepG2 cells, reduced
the number of cell surface LDLR in a dose- and time-
dependent manner. Thus, it may seem that PCSK9 has to
be secreted and taken up by the cells in order to shuttle the
LDLR from recycling endosomes to a late endosomes and
eventually to lysosomes. However, more studies are
needed to determine the exact mechanisms by which
PCSK9 degrades the LDLR intracellularly.
Conclusion
Degradation of the LDLR by PCSK9 is not mediated by a
secreted protein acted upon by PCSK9 extracellularly. Also
the PCSK9-mediated degradation of the LDLR does not
take place on the cell surface. Rather, the PCSK9-mediated
degradation of the LDLR appears to take place intracellu-
larly and occurs even when endocytosis through clathrin-
coated pits is blocked by hypertonic medium.
Methods
Mutagenesis of PCSK9
D374Y-PCSK9-FLAG plasmid containing mutation
D374Y was made by site-directed mutagenesis of the WT
PCSK9 plasmid (pCMV-PCSK9-FLAG) which contains the
sequence for the FLAG epitope tag fused to the 3' end of
the PCSK9 coding sequence, as previously described [21].BMC Cell Biology 2007, 8:9 http://www.biomedcentral.com/1471-2121/8/9
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To create the D374Y-PCSK9-His plasmid, D374Y-PCSK9
was first amplified using the D374Y-PCSK9-FLAG plas-
mid as a template and the 5' primer: 5'-CACCAT-
GGGCACCGTCAGCTCCAG-3' and 3' primer: 5'-
CTGGAGCTCCTGGGAGGCCTGCGC-3'. The PCR prod-
uct was cloned into pcDNA3.1D/V5-His-TOPO with
pcDNA3.1 Directional TOPO Expression Kit (Invitrogen,
Carlsbad, CA). The resulting fusion protein (D374Y-
PCSK9-His) contains D374Y-PCSK9 fused to a 47 amino
acid peptide containing the V5 and His epitope tags. The
WT-PCSK9-His plasmid was created by site-directed muta-
genesis of the D374Y-PCSK9-His plasmid using the 5'
primer: 5'-CATTGGTGCCTCCAGCGACTGCAGCAC-
CTGC-3' and 3' primer: 5'-GCAGGTGCTGCAGTCGCT-
GGAGGCACCAATG-3'. An expression vector that encodes
WT- PCSK9 followed by a red fluorescent protein was con-
structed as follows. The WT-PCSK9-FLAG plasmid was
used as template for amplification of WT-PCSK9 using the
primers: 5' primer; 5'-CCCTCGAGATGGGCACCGT-
CAGCTCCAGGCGG-3', 3' primer; 5'-ATCCCGGGCCT-
GGAGCTCCTGGGAGGCCTGCGCCA-3'. The 5' primer
contained a XhoI restriction site, and the 24 first nucleo-
tide of the translated part of the PCSK9  gene. The 3'
primer contained a SmaI site and the last 27 nucleotides
of the translated part of the PCSK9 gene. The stop codon
was not included in the 3'-primer. The amplified PCR
product was digested with XhoI and SmaI (New England
Biolabs Inc., Ipswich, MA). The digested products were
separated by agarose gel electrophoresis. The relevant
band was excised and purified prior ligation into a simi-
larly digested pDsRed-Express-N1 plasmid (Clontech Lab-
oratories, Inc., Palo Alto, CA) to generate WT-PCSK9-Red.
The integrity of the plasmids was confirmed by DNA
sequencing. An empty plasmid, pcDNA3.1/c-myc-His
(Invitrogen), was used as a negative control in transfec-
tion experiments.
Production of conditioned medium from transiently 
transfected HepG2 cells
HepG2 cells (The European Collection of Cultured Cells,
Wiltshire, UK) were cultured in Modified Eagle's medium
(MEM) (Gibco, Carlsbad, CA), containing penicillin (50
U/ml), streptomycin (50 μg/ml), L-glutamine (2 mM)
and 10% fetal calf serum (Invitrogen) in a humidified
atmosphere (37°C, 5% CO2). For transient transfection
experiments, HepG2 cells were seeded in 75 cm2 collagen-
coated flasks (BD Biosciences, San Diego, CA) and grown
to 80% confluency. The cells were transiently transfected
with PCSK9-containing plasmids or with empty plasmid
using Fugene-6 Reagent (Roche Diagnostics GmbH, Man-
nheim, Germany) according to the manufacturer's
instructions. A ratio of 6:1 reagent to plasmid DNA was
used during transfections. Transfection efficiencies were
in the range of 10–20%. 24 h after transfection, the trans-
fection solution was removed and the cells were washed
once with phosphate-buffered saline (PBS) before addi-
tion of 15 ml serum-free OptiMEM medium (Gibco).
After a further 24 h incubation, the medium was removed
and centrifuged for 5 min at 3000 rpm. This medium is
referred to as conditioned medium. Constructs with a His
sequence tag were used to generate PCSK9-His fusion pro-
teins in order to enable immobilization of PCSK9-His on
a nickel-chelating resin. Conditioned media from cells
transfected with PCSK9-His constructs were also used for
incubations with membrane fractions and with a prepara-
tion of truncated LDLR lacking the cytoplasmic and trans-
membrane domains as well as the experiments involving
hypertonic media. For the other experiments, PCSK9 con-
structs with a FLAG sequence tag were used. The LDLR-
degrading activity of conditioned medium from HepG2
cells transiently transfected with D374Y-PCSK9-FLAG
plasmid, was maintained for at least two weeks when
stored at 4°C (data not shown).
Western blot analysis
Cells were lysed in a buffer containing 1% Triton X-100,
100 mM NaCl, 10 mM EDTA, 20 mM Tris-HCl (pH 7.5).
Cell lysates equivalent to 20 μg protein, or membrane
fractions equivalent to 10 or 15 μg were separated by gel
electrophoresis using a 4–20% Tris-HCl Criterion Precast
Gel (Bio-Rad, Hercules, CA). The proteins were then elec-
trophoretically transferred to an Immun-Blot PVDF Mem-
brane for Protein Blotting (Bio-Rad). Non-specific
binding sites were blocked in 5% Blotting Grade Blocker
Non-Fat Dry Milk (Bio-Rad) for 1 h or overnight, and the
membrane was immunostained for 1 h. The antibodies
used were rabbit IgG anti-LDLR (1:1000, Progen Biotech-
nik GmbH, Heidelberg, Germany), rabbit IgG anti-PCSK9
(1:200, Cayman Chemical Company, Ann Arbor, MI),
mouse anti-human transferrin receptor (1:1000, Zymed,
San Fransisco, CA), mouse IgG anti-human CD71
(1:1000, Nordic Biosite, Täby, Sweden) and mouse anti-
FLAG M2 monoclonal antibody (1:3000, Sigma-Aldrich
Corp., St. Louis, MO). After incubation with the primary
antibody the membranes were washed twice in Tris-buff-
ered saline (TBS) containing 0.1% Tween-20 (Sigma-
Aldrich Corp.) and incubated for 1 h with sheep anti-rab-
bit IgG or sheep anti-mouse IgG (Amersham Biosciences,
Little Calfont, UK), both conjugated with horseradish per-
oxidase. After two more washing steps with TBS contain-
ing 0.1% Tween-20, the bands were visualized with
SuperSignal West Dura Extended Duration Substrate
(Pierce Biotechnology, Rockford, IL) and chemilumines-
cence was detected on a ChemiDoc XRS (Bio-Rad). Quan-
tity One version 4.4.0 software (Bio-Rad) was used for
quantification of band intensities.BMC Cell Biology 2007, 8:9 http://www.biomedcentral.com/1471-2121/8/9
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Flow cytometric analysis of internalization of LDL and cell 
surface LDLR
A FACS Canto flow cytometer (BD Biosciences) was used
to determine the amounts of LDL internalized by cultured
cells and the amounts of cell surface LDLR, as previously
described [21]. Briefly, LDL was fluorescently labelled
with 1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocy-
anine perchlorate (DiD) (Molecular Probes, Eugene, OR),
added to the cells (final conc. 10 μg/ml) and incubated for
2 h at 37°C. Cell surface LDLR were labelled with anti-
LDLR IgG-C7 mouse monoclonal antibody (1:20, Progen
Biotechnik) and counter-stained with Alexa Fluor® 488
goat anti-mouse IgG (H+L) (1:400, Molecular Probes).
The amount of LDL internalized and cell surface LDLR
were then determined by flow cytometry. LDLR levels
were corrected for unspecific staining by labelling the cells
with secondary antibody only.
Gel filtration of conditioned medium
Conditioned medium was concentrated approximately 10
times using BJP concentrators (Pro-Chem Inc., Littleton,
MA) and 1 ml was loaded on a Superdex 200 gel filtration
column (Pharmacia Fine Chemicals, Uppsala, Sweden).
PBS was used for elution at a flow rate of 1 ml/min and
fractions of 2 ml were collected. Gel Filtration Standard
(Bio-Rad) containing five different proteins with molecu-
lar weights ranging from 1.35 to 670 kDa was used
together with ferritin (440 kDa) for size determination. To
study the ability of the fractions to reduce the internaliza-
tion of LDL, HepG2 cells were incubated with the differ-
ent fractions for 3 h at 37°C. Fluorescently labelled LDL
was then added and the cells were incubated for another
2 h at 37°C. The amounts of LDL internalized were deter-
mined by flow cytometry.
Preparation of a truncated LDLR lacking the cytoplasmic 
and membrane-spanning domains
An LDLR construct encoding the 21 amino acids of the
signal peptide, the 767 amino acids extracellular domain
and the first amino acid of the membrane-spanning
domain, was constructed by mutagenesis of the plasmid
pcDNA4-LDLR-EYFP [29] which contains the coding
sequence of the LDLR. This construct encodes the extracel-
lular (EC) part of the LDLR. The primers used to amplify
the truncated LDLR were: 5' primer: 5'-CTTGGTACCAG-
CATGGGGCCCTGGGGCTGGAAATTGC-3', 3' primer: 5'-
CGAGCGGCCGCAGCCCTCACGCTACTGGGCTTCTTC.
The 5' primer contained a KpnI restriction site, a Kozak
sequence and the first 25 nucleotides of the translated part
of the LDLR cDNA. The 3' primer contained a NotI site
and nucleotides 2343–2467 of the LDLR  cDNA. The
amplified PCR product was TA-cloned into the pCR® 2.1-
TOPO vector of the TOPO TA cloning kit (Invitrogen)
according to the instructions by the manufacturer. The
resulting pCR® 2.1-EC-LDLR plasmid was digested with
KpnI and NotI (new England Bioloabs, Inc.), and the frag-
ments were separated by agarose gel electrophoresis. The
band corresponding to EC-LDLR was cut out of the gel
and purified by QIAquick gel extraction kit (Qiagen,
Hilden, Germany) prior to ligation into a similarly
digested pcDNA3.1/c-myc-His plasmid (Invitrogen) to
generate pcDNA3.1-EC-LDLR-His. This plasmid contains
the truncated LDLR cDNA fused to the c-myc and His
sequence tags. The integrity of the plasmid was verified by
DNA sequencing. The truncated LDLR (EC-LDLR-His)
without the cytoplasmic and membrane-spanning
domains, was prepared from media of HepG2 cells tran-
siently transfected with the pcDNA3.1-EC-LDLR-His plas-
mid. 5 ml of medium containing secreted EC-LDLR-His
was concentrated to 200 μl using BJP protein concentators
(Pro-Chem Inc.). 10 μl of this concentrated medium was
then added to 50 μl conditioned medium containing
either WT-PCSK9-His or D374Y-PCSK9-His. Conditioned
medium from HepG2 cells transfected with empty plas-
mid was used as a control. After incubation for 3 h at
37°C, 20 μl was subjected to western blot analysis in
order to quantify the amount of EC-LDLR-His.
Cell membrane preparations
HepG2 cells were cultured in serum-free OptiMEM
medium overnight and harvested by scraping. After soni-
cation, the cells were centrifuged at 500 g for 10 min. The
supernatant was removed and centrifuged at 100 000 g for
60 min in a Beckman Coulter Optima LE-80K ultracentri-
fuge (Beckman Coulter, Fullerton, CA) using an ultrarotor
70TI (Beckman Coulter). The pellet containing the cell
membranes was dissolved in PBS. 25 μl of cell mem-
branes was incubated with 25 μl conditioned medium
from HepG2 cells transiently transfected with empty plas-
mid, WT-PCSK9-His plasmid or D374Y-PCSK9-His plas-
mid.
Affinity chromatography of His-tagged fusion proteins
WT-PCSK9-His or D374Y-PCSK9-His secreted from
HepG2 cells transiently transfected with WT-PCSK9-His
or D374Y-PCSK9-His plasmids were isolated from 2 ml of
culture medium added 500 μl 5× Native Purification
Buffer with imidazole (final conc. 30 mM) using the
ProBond Purification System (Invitrogen) according to
the manufacturer's instructions. The Resin-Purification
Column contains Nickel-Chelating Resin which selec-
tively binds His-tagged recombinant fusion proteins. The
cleared medium was sequentially dialyzed against PBS
and OptiMEM serum-free medium at 4°C using a Slide-A-
Lyzer Dialysis Cassette (10 000 MWCO, Pierce Biotech-
nology).
LDLR in hypertonic medium
Hypertonic medium was prepared by a slight modifica-
tion of the method described by Krämer-Guth et al. [25].BMC Cell Biology 2007, 8:9 http://www.biomedcentral.com/1471-2121/8/9
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30  μl of 5.0 M NaCl was added per ml of OptiMEM
medium to increase he final concentration of NaCl by 150
mmol/l. The hypertonic medium was added to untrans-
fected HepG2 cells for a 30 min preincubation at 37°C.
The hypertonic medium was replaced with conditioned
medium from transiently transfected HepG2 cells which
had been made hypertonic after it had been removed
from the transfected cells. The amount of cell surface
LDLR in untransfected HepG2 incubated with hypertonic,
conditioned medium, was determined by flow cytometry
as previously described.
Degradation of the LDLR in the presence of nocodazole or 
ammonium chloride
HepG2 cells were seeded in 25 cm2 flasks (106 cells/flask)
and cultured overnight. Nocodazole (Sigma-Aldrich
Corp., final conc. 20 μg/ml) or ammonium chloride
(Sigma-Aldrich Corp., final conc. 10 mM) was added to
the cells and incubated for 30 min at 37°C. Medium was
then replaced with conditioned medium containing noc-
odazole or ammonium chloride (final conc. 20 μg/ml and
10 mM, respectively). After incubation (3 h, 37°C), the
cells were washed twice in PBS and harvested by cell scrap-
ing. Cell membranes were isolated with Compartmental
Protein Extraction Kit (Chemicon International, Temecula
CA) according to the manufacturer's instructions. Yields
were typically 60–100 μg of membrane proteins per flask
of which 10 μg were used for western blot analysis.
Statistical analysis
Comparisons between groups were performed by Stu-
dent's two-tailed t-test. Values are reported as mean (±
SD).
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